|
| | Trastuzumab Basic information | | Uses |
| Product Name: | Trastuzumab | | Synonyms: | Herceptin;TrastuzuMab(Herceptin);TRASTUZUMAB 98 % +;IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer;TRASTUZUMAB 95 % +;Anti HER2, Ig gamma-1 chain C region;Recombinant humanized anti-HER2 antibody;RhuMab HER2 | | CAS: | 180288-69-1 | | MF: | C10H14N6O5 | | MW: | 298.25536 | | EINECS: | | | Product Categories: | | | Mol File: | 180288-69-1.mol |  |
| | Trastuzumab Chemical Properties |
| storage temp. | Store at -20°C |
| | Trastuzumab Usage And Synthesis |
| Uses | Trastuzumab is used to treat breast cancer. It is effective against tumors that overexpress the HER2/neu protien. As part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu positive cancer. | | Uses | Trastuzumab is used to treat breast cancer. It is effective against tumors that overexpress the HER2/neu protien. As part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu positive cancer. | | Indications | The introduction of herceptin (Trastuzumab) into clinical
practice for the treatment of breast cancer marks a
major advance in the use of monoclonal antibody cancer
therapy. Herceptin is a humanized antibody directed
against the HER-2 antigen that is overexpressed
on the tumor cell surface in approximately 25% of
breast cancer patients. HER-2/neu/erbB2 overexpression
marks an aggressive estrogen receptor–negative
form of breast cancer. Therefore, a therapeutic agent
selective for this target is particularly valuable.
Herceptin is administered by intravenous infusion and
in conjunction with paclitaxel can extend survival in
patients with HER-2/neu/erbB2 overexpressing metastatic
breast cancer.Herceptin use is associated with infusion-
related hypotension, flushing and bronchoconstriction,
and skin rash but no bone marrow toxicity.
Herceptin appears to sensitize patients to cardiotoxicity,
an important concern in patients also receiving
doxorubicin. |
| | Trastuzumab Preparation Products And Raw materials |
|
